FATE · Insider Trading
Fate Therapeutics, Inc.
Every open-market purchase and sale reported by FATE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | Kamal Adawi | Chief Financial Officer | Sell | −6,582 | −$13.52K |
| 2026-08-05 | Cindy Tahl | See Remarks | Sell | −38,800 | −$95.41K |
| 2026-08-05 | Bahram Valamehr | President and CEO | Sell | −43,947 | −$108.10K |
| 2026-06-15 | Matt Abernethy | Director | A | +87,900 deriv. | — |
| 2026-06-15 | Robert S Epstein | Director | A | +87,900 deriv. | — |
| 2026-06-15 | Shefali Agarwal | Director | A | +87,900 deriv. | — |
| 2026-06-15 | Laura Hamill | Director | A | +175,800 deriv. | — |
| 2026-06-15 | William H Rastetter | Director | A | +87,900 deriv. | — |
| 2026-06-15 | Jeremy Green | Director | A | +87,900 deriv. | — |
| 2026-06-15 | Yuan Xu | Director | A | +87,900 deriv. | — |
| 2026-06-15 | Karin Jooss | Director | A | +87,900 deriv. | — |
| 2026-06-15 | Michael Stewart Lee | Director | A | +87,900 deriv. | — |
| 2026-05-21 | Bahram Valamehr | President and CEO | Sell | −28,946 | −$54.48K |
| 2026-05-21 | Cindy Tahl | See Remarks | Sell | −25,590 | −$48.08K |
| 2026-05-07 | Cindy Tahl | See Remarks | M | +166,664 | +$208.00K |
| 2026-05-06 | Robert S Epstein | Director | M | +25,000 | +$42.25K |
| 2026-05-06 | William H Rastetter | Director | M | +25,000 | +$42.25K |
| 2026-04-23 | Jeremy Green | Director | J | — | — |
| 2026-04-22 | Jeremy Green | Director | J | — | — |
| 2026-01-16 | Kamal Adawi | Chief Financial Officer | A | +25,000 | — |
| 2026-01-16 | Cindy Tahl | See Remarks | A | +100,000 | — |
| 2026-01-16 | Bahram Valamehr | President and CEO | A | +335,000 | — |
| 2026-01-12 | Bahram Valamehr | President and CEO | Sell | −5,190 | −$5.56K |
| 2026-01-12 | Cindy Tahl | See Remarks | Sell | −10,589 | −$11.28K |
| 2025-10-21 | Kamal Adawi | Chief Financial Officer | A | +75,000 | — |
| 2025-08-05 | Cindy Tahl | See Remarks | Sell | −9,037 | −$9.57K |
| 2025-08-05 | Bahram Valamehr | President and CEO | Sell | −14,466 | −$15.40K |
| 2025-05-30 | Neelufar Mozaffarian | Director | A | +55,000 deriv. | — |
| 2025-05-30 | Matt Abernethy | Director | A | +110,000 deriv. | — |
| 2025-05-30 | Yuan Xu | Director | A | +55,000 deriv. | — |
| 2025-05-30 | Michael Stewart Lee | Director | A | +55,000 deriv. | — |
| 2025-05-30 | Karin Jooss | Director | A | +55,000 deriv. | — |
| 2025-05-30 | Shefali Agarwal | Director | A | +55,000 deriv. | — |
| 2025-05-30 | Robert S Epstein | Director | A | +55,000 deriv. | — |
| 2025-05-30 | Jeremy Green | Director | A | +55,000 deriv. | — |
| 2025-05-30 | John Mendlein | Director | A | +55,000 deriv. | — |
| 2025-05-30 | William H Rastetter | Director | A | +55,000 deriv. | — |
| 2025-01-16 | Bahram Valamehr | President and CEO | A | +1,300,000 deriv. | — |
| 2025-01-16 | Cindy Tahl | See Remarks | A | +70,000 | — |
| 2025-01-16 | Jerome Charles Bressi | See Remarks | A | +65,000 | — |
| 2025-01-13 | Bahram Valamehr | President and CEO | Sell | −8,705 | −$13.41K |
| 2025-01-13 | Cindy Tahl | See Remarks | Sell | −5,654 | −$8.76K |
| 2025-01-13 | Jerome Charles Bressi | See Remarks | Sell | −5,980 | −$9.27K |
| 2024-12-26 | Jeremy Green | Director | MIXED | +56,331 | +$94.64K |
| 2024-12-16 | Jeremy Green | Director | C | +30,110 | — |
| 2024-08-07 | Yuan Xu | Director | Sell | −633 | −$2.68K |
| 2024-07-31 | Cindy Tahl | General Counsel and Secretary | A | +200,000 | — |
| 2024-07-31 | Bahram Valamehr | Chief R&D Officer | A | +200,000 | — |
| 2024-07-31 | Neelufar Mozaffarian | Director | A | +80,000 deriv. | — |
| 2024-06-11 | Jeremy Green | Director | A | +40,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jeremy Green | Director | 12,884,277 | $25.00M |
| Bahram Valamehr | President and CEO | 591,815 | $1.15M |
| Cindy Tahl | See Remarks | 589,355 | $1.14M |
| William H Rastetter | Director | 495,603 | $961.47K |
| Jerome Charles Bressi | See Remarks | 335,203 | $650.29K |
| John Mendlein | Director | 311,231 | $603.79K |
| Kamal Adawi | Chief Financial Officer | 93,418 | $181.23K |
| Robert S Epstein | Director | 36,331 | $70.48K |
| Michael Stewart Lee | Director | 11,331 | $21.98K |
| Shefali Agarwal | Director | 10,490 | $20.35K |
| Karin Jooss | Director | 9,848 | $19.11K |
| Yuan Xu | Director | 8,669 | $16.82K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FATE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.